Table 2

Association of CYP3A4 genotype and clinical characteristics among African-American prostate cancer cases

Clinical characteristicCYP3A4 genotype, n (%)aOR (95% CI)b
AAAGGG
Gleason grade
 ≤727 (19%)54 (37%)64 (44%)1.0
 >73 (10%)10 (34%)16 (55%)1.6 (0.7–3.6)
PSA at diagnosisc
 ≤1013 (20%)25 (39%)26 (41%)1.0
 >1016 (15%)39 (36%)53 (49%)1.6 (0.8–3.1)
TNM stage
 T1a–c/T2a–b24 (17%)51 (37%)64 (46%)1.0
 T2c/T3/T4/M6 (17%)13 (37%)16 (46%)1.0 (0.5–2.2)
Grade/Staged
 Low23 (19%)48 (39%)53 (43%)1.0
 High7 (14%)16 (32%)27 (54%)1.7 (0.9–3.4)
  • a n, number of subjects. A, wild type; G, variant.

  • b Comparing those with GG versus those with AA and AG genotypes (recessive model). Adjusted for age at diagnosis and family history of prostate cancer.

  • c Units for PSA, ng/ml.

  • d Combined Gleason grade and TNM stage is defined as: Low, T1a–T1c or T2a–b stage and Gleason grade ≤7; High, T2c, T3, T4, or M stage and Gleason grade >7. Gleason grading is detailed in Gleason (8) and TNM staging in Spiessl (9) .